

## LeMaitre Announces Pricing of Public Offering of Common Stock

July 14, 2021

BURLINGTON, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices, implants and services, today announced the pricing of an underwritten public offering of 1,000,000 shares of its common stock at a public offering price of \$54.50 per share. Gross proceeds to LeMaitre from the offering are expected to be approximately \$54.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by LeMaitre. The offering is expected to close on or about July 16, 2021, subject to customary closing conditions. LeMaitre has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 150,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Jefferies and Stifel are acting as joint book-running managers for the proposed offering. KeyBanc Capital Markets is acting as co-lead manager, and Barrington Research, Lake Street Capital Markets, LLC and Sidoti & Company, LLC are acting as co-managers.

LeMaitre intends to use the net proceeds from the offering to repay in full borrowings outstanding under its senior secured credit facility and for general corporate purposes, including working capital and capital expenditures and payments under its quarterly dividend program. LeMaitre may also use a portion of the net proceeds to fund potential future acquisitions.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on June 1, 2020. The offering is being made only by means of a written prospectus and prospectus supplement that forms a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the offering has been previously filed with the SEC and is available on the SEC's website at [www.sec.gov](http://www.sec.gov). Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at [prospectus\\_department@jefferies.com](mailto:prospectus_department@jefferies.com), or by telephone at (877) 821-7388; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by telephone at 415-364-2720 or by email at [syndprospectus@stifel.com](mailto:syndprospectus@stifel.com).

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

### About LeMaitre

LeMaitre is a provider of devices for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. LeMaitre develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.

### Forward-Looking Statements

*To the extent that statements contained in this press release are not descriptions of historical facts regarding LeMaitre, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995, including LeMaitre's expected use of the proceeds of the proposed public offering. Such forward-looking statements involve substantial risks and uncertainties that could cause LeMaitre's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. LeMaitre undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to LeMaitre's business in general, please refer to LeMaitre's prospectus supplement to be filed with the SEC, including the documents incorporated by reference therein, which include LeMaitre's Annual Report on Form 10-K filed with the SEC on March 12, 2021, LeMaitre's Quarterly Report on Form 10-Q filed with the SEC on May 10, 2021, and LeMaitre's other periodic reports filed with the SEC.*

### Investor Relations Contacts:

David Roberts  
President  
LeMaitre Vascular, Inc.  
781-425-1693  
[droberts@lemaitre.com](mailto:droberts@lemaitre.com)

J.J. Pellegrino  
Chief Financial Officer  
LeMaitre Vascular, Inc.  
781-425-1691  
[jpellegrino@lemaitre.com](mailto:jpellegrino@lemaitre.com)



Source: LeMaitre Vascular, Inc.